Patents by Inventor Robert McKay
Robert McKay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220363671Abstract: Described herein are glue degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment or prevention of conditions, diseases, and disorders mediated by various target proteins.Type: ApplicationFiled: September 16, 2020Publication date: November 17, 2022Inventors: Jake AXFORD, Rohan Eric John BECKWITH, Simone BONAZZI, Nicole BUSCHMANN, Artiom CERNIJENKO, Janetta DEWHURST, Aleem FAZAL, Matthew James HESSE, Lauren HOLDER, Viktor HORNAK, Hidetomo IMASE, Rama JAIN, Xianming JIN, John Ryan KERRIGAN, Julie LACHAL, Fupeng MA, Hasnain Ahmed MALIK, James R. MANNING, Daniel MCKAY, Robert Joseph MOREAU, Pierre NIMSGERN, Gary O'BRIEN, Anna VULPETTI, Ken YAMADA, Junping ZHAO
-
Patent number: 11417168Abstract: An overhead display assembly includes a display monitor coupled to a monitor tray. The monitor tray is positionable in an operational position and a maintenance position. A support stanchion has an anchoring part, a coupling part, and a stanchion body extending from the anchoring part to the coupling part. The anchoring part is coupleable to a fixed vertical or horizontal supporting structure. A counter-balanced hinging mechanism has one or more pivots upon which monitor tray is configured to rotate with respect to said support stanchion. A force producing device is configured to apply a variable amount of force to the monitor tray based upon a position of the display monitor, the variable amount of force being at least a force sufficient to maintain the monitor tray stationary in an intermediate position between the operational position and the maintenance position.Type: GrantFiled: November 18, 2020Date of Patent: August 16, 2022Assignee: ARISTOCRAT TECHNOLOGIES AUSTRALIA PTY LIMITEDInventors: Rena Schoonmaker, Bruce Urban, Matthew McKay, Noel Voloh, Robert Wand, Gary Strahinic
-
Publication number: 20170228726Abstract: A system may transmit a time-based token to the merchant device. The system may receive a second merchant session key, a customer session key, a customer ID, a customer device certificate, and a second transaction amount from a customer device. The system may further match the first merchant session key to the second merchant session key, and transmit the time-based token to the customer device in response to the first merchant session key matching the second merchant session key.Type: ApplicationFiled: February 4, 2016Publication date: August 10, 2017Applicant: AMERICAN EXPRESS TRAVEL RELATED SERVICES COMPANY, INC.Inventors: Billy Bohanan, Brady Cullimore, Justin Flaishans, Dinesh Gudibandi, Sean Maize, Robert Mckay, ShahanasSalam NaduvilePurayil, Rakesh Pattanayak, Dan Sorensen, Andrew Sosnicki
-
Patent number: 9617540Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.Type: GrantFiled: April 28, 2015Date of Patent: April 11, 2017Assignee: Ionis Pharmaceuticals, Inc.Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
-
Patent number: 9447591Abstract: A tool for finishing an outside corner comprises a handle and a V-shaped blade coupled to the handle. The V-shaped blade has a pair of planar blade surfaces which each extend from a vertex thereof. A retaining mechanism releasably retains a sponge against the surfaces of the V-shaped blade.Type: GrantFiled: September 15, 2014Date of Patent: September 20, 2016Inventor: Robert McKay
-
Publication number: 20150344879Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.Type: ApplicationFiled: April 28, 2015Publication date: December 3, 2015Applicant: ISIS PHARMACEUTICALS, INC.Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
-
Patent number: 9071974Abstract: Methods, systems, and software for mediating SMS messages, and especially type 0 SMS messages, in a wireless mobile communications device configured to send and receive data using a GSM protocol and including a subscriber identity module (“SIM”) including electronic hardware and computer software executed by the hardware such that the SIM is configured to send, receive, and process messages using a Short Message System (“SMS”) between the wireless mobile communications device and a communications network. One aspect includes a method for mediating SMS messages comprising: configuring electronic hardware on the wireless mobile communications device to implement a firewall on the wireless mobile communications device, the firewall configured to identify and optionally mediate infrastructure SMS messages.Type: GrantFiled: June 28, 2009Date of Patent: June 30, 2015Assignee: Oceans Edge, Inc.Inventors: Robert McKay, Sam Emara, Steve Hildner, Thomas Shanley, Wesley Driver, Jay Lukin, Terry Bahr, Tim Berzins, Mihaela Mihaylova, Nathan Klonoski
-
Publication number: 20150167323Abstract: A tool for finishing an outside corner comprises a handle and a V-shaped blade coupled to the handle. The V-shaped blade has a pair of planar blade surfaces which each extend from a vertex thereof. A retaining mechanism releasably retains a sponge against the planar blade surfaces V-shaped blade.Type: ApplicationFiled: September 15, 2014Publication date: June 18, 2015Inventor: Robert McKay
-
Patent number: 9045754Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.Type: GrantFiled: May 7, 2007Date of Patent: June 2, 2015Assignee: Isis Pharmaceuticals, Inc.Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
-
Patent number: 8969316Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.Type: GrantFiled: October 26, 2012Date of Patent: March 3, 2015Assignee: Isis Pharmaceuticals, Inc.Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
-
Publication number: 20150057329Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.Type: ApplicationFiled: March 17, 2014Publication date: February 26, 2015Applicant: Isis Pharmaceuticals, Inc.Inventors: Sanjay BHANOT, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
-
Publication number: 20140357856Abstract: The present invention relates to novel chimeric oligomeric compounds having a plurality of alternating regions having either RNA like having northern or 3?-endo conformational geometry (3?-endo regions) or DNA like having southern or C2?-endo/O4?-endo conformational geometry. The oligomeric compounds of the present invention have shown reduction in mRNA levels in multiple in vitro and in vivo assay systems and are useful, for example, for investigative and therapeutic purposes.Type: ApplicationFiled: June 13, 2014Publication date: December 4, 2014Applicant: ISIS PHARMACEUTICALS, INC.Inventors: Brett P. Monia, Madeline M. Butler, Robert McKay, Brenda F. Baker
-
Patent number: 8853178Abstract: Compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.Type: GrantFiled: July 6, 2011Date of Patent: October 7, 2014Assignee: Isis Pharmaceuticals, Inc.Inventors: Sanjay Bhanot, Lex M. Cowsert, Jacqueline R. Wyatt, Brett P. Monia, Madelline M. Butler, Robert McKay, Susan M. Freier, Kenneth W. Dobie
-
Publication number: 20140275207Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of LMW-PTPase in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are methods for the prevention, amelioration and/or treatment of diabetes, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, dyslipidemia, hyperlipidemia, hypertriglyceridemia, and hyperfattyacidemia. In some embodiments, the diabetes is type II diabetes by administration of antisense compounds targeted to LMW-PTPase.Type: ApplicationFiled: March 14, 2013Publication date: September 18, 2014Applicant: ISIS PHARMACEUTICALS, INC.Inventors: Sanjay K. Pandey, Robert McKay, Sanjay Bhanot, Xing-Xian Yu
-
Patent number: 8791083Abstract: The present invention relates to novel chimeric oligomeric compounds having a plurality of alternating regions having either RNA like having northern or 3?-endo conformational geometry (3?-endo regions) or DNA like having southern or C2?-endo/O4?-endo conformational geometry. The oligomeric compounds of the present invention have shown reduction in mRNA levels in multiple in vitro and in vivo assay systems and are useful, for example, for investigative and therapeutic purposes.Type: GrantFiled: February 19, 2009Date of Patent: July 29, 2014Assignee: Isis Pharmaceuticals, Inc.Inventors: Brett P. Monia, Madeline M. Butler, Robert McKay, Brenda F. Baker
-
Patent number: 8673871Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.Type: GrantFiled: May 7, 2007Date of Patent: March 18, 2014Assignee: Isis Pharmaceuticals, Inc.Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
-
Patent number: 8642753Abstract: Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for diagnosis and treatment of disease associated with expression of glucagon receptor are provided.Type: GrantFiled: August 3, 2012Date of Patent: February 4, 2014Assignee: Isis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Kenneth W. Dobie, Robert McKay, Sanjay Bhanot
-
Patent number: 8586554Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.Type: GrantFiled: May 7, 2007Date of Patent: November 19, 2013Assignee: Isis Pharmaceuticals, Inc.Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
-
Patent number: D955836Type: GrantFiled: September 15, 2020Date of Patent: June 28, 2022Inventor: Robert McKay
-
Patent number: D955924Type: GrantFiled: September 5, 2019Date of Patent: June 28, 2022Assignee: Thor Tech, Inc.Inventors: James Jack Owen Devine, Dale Beever, Raymond McKay Featherstone, Bryan M. Fox, Dana Kim Gehman, Bradley J. Mitchell, Robert Owen Sanford, Bryan Thompson